vTv Therapeutics

Yahoo Finance • 4 days ago

Small-cap healthcare stocks with A+ grade EPS revisions ahead of earnings

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As Q1 2026 earnings season approaches, the healthcare sector enters reporting season as one of the market's primary... Full story

Yahoo Finance • 7 days ago

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HIGH POINT, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to i... Full story

Yahoo Finance • last month

vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026 Strengthened balance sheet provides funding runway well past... Full story

Yahoo Finance • last month

vTv Therapeutics (VTVT) Secures Global Partnership for PDE4 Inhibitor HPP737

vTv Therapeutics Inc. (NASDAQ:VTVT) is one of the most promising micro-cap stocks according to analysts. On February 2, vTv Therapeutics expanded its partnership with Newsoara Biopharma Co. Ltd., transforming a regional agreement into a gl... Full story

Yahoo Finance • 2 months ago

vTv Therapeutics to Participate in Upcoming Investor Conferences

HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to in... Full story

Yahoo Finance • 4 months ago

vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health

HIGH POINT, N.C., Dec. 18, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced a Phase 2 clinical study protocol developed in collaboration with M42’s Insights Research O... Full story

Yahoo Finance • 5 months ago

vTv Therapeutics GAAP EPS of -$1.08 misses by $0.11

* vTv Therapeutics press release [https://seekingalpha.com/pr/20298026-vtv-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate-update] (VTVT [https://seekingalpha.com/symbol/VTVT]): Q3 GAAP EPS of -$1.08 miss... Full story

Yahoo Finance • 5 months ago

vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced issuance of new U.S. patent covering crysta... Full story

Yahoo Finance • 6 months ago

vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

HIGH POINT, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, today announced the appointment of Alfonso Galderisi, MD, PhD,... Full story

Yahoo Finance • 6 months ago

vTv Therapeutics registers 15.9M Class A shares for potential resale

* vTv Therapeutics (VTV [https://seekingalpha.com/symbol/VTV]) registered 15.88M Class A common shares for resale by selling stockholders. * Includes 2.13M outstanding shares, plus shares issuable from warrants: 8.47M shares via pre-fu... Full story

Yahoo Finance • 6 months ago

ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan... Full story

Yahoo Finance • 7 months ago

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to i... Full story

Yahoo Finance • 8 months ago

VTV Therapeutics Inc-CL A (NASDAQ:VTVT) Reports Wider Q2 2025 Loss Amid Clinical-Stage Progress

VTV THERAPEUTICS INC-CL A (NASDAQ:VTVT [https://www.chartmill.com/stock/quote/VTVT/profile]) reported its second-quarter 2025 financial results, posting a net loss per share of $0.92, which was wider than the analyst consensus estimate of... Full story

Yahoo Finance • 8 months ago

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

•   First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026 •   Cadisegliatin intellectual property portfolio expanded •   Leadersh... Full story

Yahoo Finance • 8 months ago

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

HIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin b... Full story

Yahoo Finance • 11 months ago

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

HIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced the appointment of Michael Tung, M.D., MBA as Executive Vice President and Chief Financial O... Full story

Yahoo Finance • 11 months ago

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

Ongoing screening in CATT1 Phase 3 trial evaluating cadisegliatin in patients with type 1 diabetes (T1D) Topline Phase 3 data for cadisegliatin expected in 2H 2026 HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc... Full story

Yahoo Finance • last year

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appointment of Martin Lafontaine as Chief... Full story

Yahoo Finance • last year

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall duration of the trial from 12 to 6 months H... Full story

Yahoo Finance • 2 years ago

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

HIGH POINT, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatme... Full story